GOSS Gossamer Bio, Inc.
$9.77▲ +6.78%
Healthcare
Other
After hours
$9.80▲ +0.31%
Oct 27, 5:40 PM ET
Volume 137.8K
Avg Volume (10D) 240.6K
Key Metrics & Fundamentals
Market Cap
$59.76M
P/E Ratio
–
Div Yield
0.00%
52W Range
8.29 - 309.60
% vs 50 MA
-14.00%
% vs 200 MA
-77.85%
RSI-14
46.7
MACD Histogram
+0.1200
Beta (1Y vs SPY)
2.17
Free Cash Flow
-$39.42M
Gross Rev
$9.24M
Gross Profit
$9.24M
EBITDA
-$29.70M
COGS
–
Operating Exp
$35.31M
Operating Income
-$26.07M
EBIT
-$26.07M
Pretax Income
$16.90M
Net Income
$16.90M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks
Simply Wall St. · Oct 16, 2026 11:20 PM ET
Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
The Fly · Oct 13, 2026 9:43 AM ET
Chardan Initiates Gossamer Bio at Buy With $160 Price Target
MT Newswires · Oct 13, 2026 5:13 AM ET
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
Simply Wall St. · Oct 1, 2026 7:12 PM ET
Gossamer Bio Files New Drug Application for Seralutinib
MT Newswires · Sep 23, 2026 5:11 PM ET
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Business Wire · Sep 23, 2026 4:01 PM ET
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Business Wire · Sep 16, 2026 4:01 PM ET
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Business Wire · Sep 11, 2026 8:00 AM ET
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Business Wire · Sep 9, 2026 9:00 AM ET
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
GlobeNewswire · Sep 8, 2026 4:31 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See GOSS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.